Sage Therapeutics, Inc. (SAGE) News
Filter SAGE News Items
SAGE News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
SAGE News Highlights
- For SAGE, its 30 day story count is now at 30.
- Over the past 24 days, the trend for SAGE's stories per day has been choppy and unclear. It has oscillated between 1 and 12.
- DRUG, MET and BIIB are the most mentioned tickers in articles about SAGE.
Latest SAGE News From Around the Web
Below are the latest news stories about Sage Therapeutics Inc that investors may wish to consider to help them evaluate SAGE as an investment opportunity.
Sage Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Highlights Pipeline and Business ProgressCAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company fearlessly leading the way to create a world with better brain health, today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2021. “2021 was a data rich year marked by important advancements in multiple disease areas across all of our brain health franchises,” said Barry Greene, chief executive officer at Sage Therapeutics. “I’m excite |
Sage Therapeutics'' (SAGE) CEO Barry Greene on Q4 2021 Results - Earnings Call TranscriptNo summary available. |
Sage Therapeutics GAAP EPS of -$2.12 beats by $0.05, revenue of $1.6M misses by $0.17MSage Therapeutics press release (SAGE): Q4 GAAP EPS of -$2.12 beats by $0.05.Revenue of $1.6M (-99.9% Y/Y) misses by $0.17M.Ended 2021 with cash balance of $1.7 billion;… |
The Zacks Analyst Blog Highlights Regeneron Pharmaceuticals, Sage Therapeutics, Biogen Agios Pharmaceuticals Atara BiotherapeuticsRegeneron Pharmaceuticals, Sage Therapeutics, Biogen Agios Pharmaceuticals Atara Biotherapeutics are included in this blog. |
Sage Therapeutics, Inc. (SAGE) Reports Q4 Loss, Misses Revenue EstimatesSage Therapeutics, Inc. (SAGE) delivered earnings and revenue surprises of 1.85% and 8.27%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock? |
Sage Therapeutics Q4 2021 Earnings PreviewSage Therapeutics (NASDAQ:SAGE) is scheduled to announce Q4 earnings results on Thursday, February 24th, before market open.The consensus EPS Estimate is -$2.16 and the consensus… |
Biotech Stock Roundup: SAGE, ATRA Down on Study Updates, AGIO Drug Approval & MoreUpdates from SAGE and Atara (ATRA) are among a few key highlights from the biotech sector during the past week. |
SAGE Therapeutics (SAGE) Receives a Hold from Mizuho SecuritiesIn a report released today, Vamil Divan from Mizuho Securities maintained a Hold rating on SAGE Therapeutics (SAGE – Research Report), with a price target of $44.00. The company's shares closed last Wednesday at $35.91, close to its 52-week low of $35.30. According to TipRanks.com, Divan is a 1-star analyst with an average return of -2.1% and a 48.1% success rate. Divan covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, ACADIA Pharmaceuticals, and Xeris Pharmaceuticals. SAGE Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $66.29, representing an 82.9% upside. |
Sage Therapeutics, Inc. (SAGE) May Report Negative Earnings: Know the Trend Ahead of Next Week's ReleaseSage Therapeutics, Inc. (SAGE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
Sage Therapeutics (SAGE) Depression Drug Meets Goal, Stock DownSage Therapeutics (SAGE) and Biogen's (BIIB) depression candidate, zuranolone given along with antidepressants improves depressive symptoms in a phase III study. Questions remain about the durability of the drug. |